© Copyright 2012 Chemical Biology Ventures Limited. All Rights Reserved. Registered in England & Wales number 7968150. Registered office: 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ. Address for correspondence: 123 Alexander Close, Abingdon, Oxfordshire, OX14 1XD
Tel: +44 (0) 1235 532481
Mob: 07836 554231
Email: [email protected]
FtsZ, a GTPase that regulates bacterial cell division has been a recognised target for novel antibacterial drug discovery for some time. Under Lloyd Czaplewski's direction, Prolysis discovered the first effective inhibitors of bacterial cell division & partnered the project with the Wellcome Trust's Seeding Drug Discovery initiative. An efficient Lead optimisation project delivered best-in-class novel antibacterials that are effective in gold-standard models of infection
Optimisation of 3-Methoxybenzamide leading to potent antibacterials with in vivo efficacy
High-throughput screens had failed to identify optimisable and progressible compounds. Alternative more advantageous starting points were required.
Lloyd Czaplewski realised that a literature compound, 3-Methoxybenzamide, which was descibed as a weak inhibitor of FtsZ was a good starting point for optimisation. It was on-target & was able to penetrate the bacterial cell. An effective medicinal chemistry Lead Optimisation project led to compounds with in vivo efficacy & competitive pharmaceutical properties.
Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown D, Baker PJ, Barynin VV, Rice DW, Sedelnikova SE, Heal JR, Sheridan JM, Aiwale ST, Chauhan PK, Srivastava A, Taneja A, Collins I, Errington J, Czaplewski LG. A novel inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321, 1673-1675.
Czaplewski LG, Collins I, Boyd EA, Brown D, East SP, Gardiner M, Fletcher R, Haydon DJ, Henstock V, Ingram P, Jones C, Noula C, Kennison L, Rockley C, Rose V, Thomaides HB, Ure R, Whittaker M Stokes NR. Antibacterial alkyloxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorganic Medicinal Chemistry Letters 2009; 19(2):524-7.
Haydon DJ, , Bennett JM, Brown D, Collins I, Lancett P, Stokes NR, Macdonald R, Chauhan PK, Sutariya JK, Nayal N, Srivastava A, Beanland J, Hall R, Henstock V, Noula C, Rockley C, Czaplewski LG. (2010). Building an antibacterial with in vivo efficacy: synthesis and characterisation of potent inhibitors of the bacterial cell-division protein FtsZ with improved pharmaceutical properties. J. Med Chem. 53, 3927-3936.
Crystal structure of Bacillus FtsZ from Haydon et al. Image prepared using PyMol. Compounds selected from published patents & papers. Left 3-MBA, right PC190723 - the result of a Lead Optimisation programme.